What Antigen-Specific T Cell Cytotoxicity Assay Services Cover
Antigen-specific T cell cytotoxicity assays measure whether effector T cells recognize and kill target cells presenting a defined antigen. Our service supports teams that need an in vitro readout of antigen-specific killing for immunotherapy, vaccine, and cell therapy research programs. Projects are scoped around your antigen, effector and target cell sources, and preferred readout, then executed with qualified assay controls and reported in a clear, review-ready format. Assay design, target cell preparation, co-culture, readout selection, and data reporting are agreed before work begins.
Complementary antigen-specific T cell response assays can characterize immune activation alongside target-cell killing.
What the Service Includes
Project-Scoped Assay Design
We define antigen format, effector and target cell sources, effector-to-target ratios, timepoints, and readout strategy with you before the study starts, so the assay fits your program rather than a fixed template.
Qualified Cytotoxicity Readouts
Killing is assessed using method-appropriate readouts selected during design, with assay controls and replicate structure agreed in the project scope. Readout choice is documented in the study plan and final report.
Structured Data Reporting
Deliverables typically include a study report with assay conditions, raw and processed readout data, control performance, and a summary of antigen-specific killing observed under the tested conditions.
How an Engagement Works
What You Receive
| Deliverable | Typical Content |
|---|---|
| Project proposal and scope document | A written proposal that defines the assay design, effector and target cell formats, readout, timeline, and responsibilities before work begins. |
| Assay-ready cell preparations | Antigen-presenting or antigen-expressing target cells and matched effector T cell preparations, with viability and identity checks recorded as scoped. |
| Cytotoxicity readout dataset | Quantified killing or viability readouts across the tested effector-to-target ratios and timepoints, delivered as a structured dataset with the raw instrument output. |
| Controls and reference wells | Background, spontaneous-release, and maximum-release control wells included as scoped, so that assay window and data quality can be assessed. |
| QC summary | A short quality summary covering cell viability at setup, control performance, and any assay acceptance notes relevant to interpreting the results. |
Why Work With Us
Assay design matched to your antigen and readout
Antigen-specific cytotoxicity projects differ in target cell format, effector source, and the readout that fits your question. We scope the design with you before the first plate is set up, so the assay measures what your program actually needs.
Controls built into every run
Background, spontaneous-release, and maximum-release controls are planned as part of the plate layout when included in scope. This gives you a clear assay window and a documented basis for judging whether a result is interpretable.
Clear reporting boundaries
Reports separate what was measured from what it may mean. Cytotoxicity readouts are presented as assay-level observations, and any interpretation beyond the tested conditions is flagged as outside the delivered scope.
Further Reading
Research reference
1. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
Nature Medicine. 2025. DOI: 10.1038/s41591-024-03418-4.
View articleDiscuss Your Antigen-Specific T Cell Cytotoxicity Assay
Share your target antigen, effector and target cell context, and the readout you need. Our team will review the design, propose an assay format and controls, and outline a project scope with timeline and deliverables before work begins.
Follow-up tumor organoid–immune cell co-culture assays can examine tumor killing in a more complex culture setting.